What can I use instead of Pirfenidone/Axri?

Pirfenidone/Pirfenidone is an anti-fibrotic drug used to treat idiopathic pulmonary fibrosis, but in some cases, patients may need to seek alternative treatments due to side effects or other factors. Although pirfenidone has shown good efficacy in clinical applications, its side effects include gastrointestinal reactions, rash, and liver function abnormalities, which may make it difficult for patients to tolerate the drug. Therefore, it is important to understand the medications that are available as alternatives.

Nintedanib (Nintedanib) is another anti-fibrotic drug used to treat idiopathic pulmonary fibrosis. Similar to pirfenidone, nintedanib slows the fibrotic process by inhibiting the action of multiple growth factors. Studies show that nintedanib can effectively improve lung function and reduce the risk of disease progression. Compared with pirfenidone, nintedanib has side effects including diarrhea and abnormal liver function, but is generally better tolerated by some patients, thus providing a viable alternative for those intolerant to pirfenidone.

Other studies in idiopathic pulmonary fibrosis are also exploring the potential of other drugs, such as anti-inflammatory drugs and immunomodulators. These drugs, such as corticosteroids, may help control inflammation and slow the progression of fibrosis in some cases. However, long-term use of glucocorticoids may cause other serious side effects and should be used with caution.

In addition, certain natural medicines and supplements have been studied as alternative treatments for fibrosis. For example, certain antioxidants such asN-acetylcysteine u200bu200b(NAC) and flavonoids have shown protective effects against pulmonary fibrosis, and although their effects are generally mild, they can be used as adjunctive therapies in combination with other drugs to enhance the therapeutic effect.

Biologics are also worthy of attention as an alternative. In recent years, biologic agents targeting pulmonary fibrosis, such as monoclonal antibodies targeting specific cytokines or signaling pathways, are being developed and studied. By targeting specific pathological mechanisms, these biologics may provide more precise and effective treatment options, especially for patients who are intolerant to traditional drugs.